Literature DB >> 19016656

Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis.

Paola Loria1, Amedeo Lonardo, Giovanni Targher.   

Abstract

NAFLD (non-alcoholic fatty liver disease) encompasses the spectrum of fatty liver disease in insulin-resistant individuals who often display T2DM (Type 2 diabetes mellitus) and obesity. The present review highlights the pathophysiological basis and clinical evidence for a possible causal linkage between NAFLD and CVD (cardiovascular disease). The role of traditional and non-traditional CVD risk factors in the pathophysiology of NAFLD is considered in the first part of the review, with the basic science shared by atherogenesis and hepatic steatogenesis discussed in depth in the second part. In conclusion, NAFLD is not an innocent bystander, but a major player in the development and progression of CVD. NAFLD and CVD also share similar molecular mechanisms and targeted treatment strategies. On the research side, studies should focus on interventions aimed at restoring energy homoeostasis in lipotoxic tissues and at improving hepatic (micro)vascular blood supply.

Entities:  

Mesh:

Year:  2008        PMID: 19016656     DOI: 10.1042/CS20070311

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  19 in total

Review 1.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

Review 2.  Nonalcoholic fatty liver disease and aging: epidemiology to management.

Authors:  Marco Bertolotti; Amedeo Lonardo; Chiara Mussi; Enrica Baldelli; Elisa Pellegrini; Stefano Ballestri; Dante Romagnoli; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

3.  The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease.

Authors:  Mariana Lazo; Jonathan Rubin; Jeanne M Clark; Josef Coresh; Andrea L C Schneider; Chiadi Ndumele; Ron C Hoogeveen; Christie M Ballantyne; Elizabeth Selvin
Journal:  J Hepatol       Date:  2014-11-27       Impact factor: 25.083

Review 4.  Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?

Authors:  G Targher; M Chonchol; I Pichiri; G Zoppini
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

5.  A role for Sp1 in transcriptional regulation of phosphatidylethanolamine N-methyltransferase in liver and 3T3-L1 adipocytes.

Authors:  Laura K Cole; Dennis E Vance
Journal:  J Biol Chem       Date:  2010-02-11       Impact factor: 5.157

6.  Pharmacological agents for nonalcoholic steatohepatitis.

Authors:  Maeva Guillaume; Vlad Ratziu
Journal:  Hepatol Int       Date:  2013-11-19       Impact factor: 6.047

7.  A simple index of lipid overaccumulation is a good marker of liver steatosis.

Authors:  Giorgio Bedogni; Henry S Kahn; Stefano Bellentani; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2010-08-25       Impact factor: 3.067

8.  Association between non-alcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test.

Authors:  A G Laurinavicius; M S Bittencourt; M J Blaha; F C Nary; N M Kashiwagi; R D Conceiçao; R S Meneghelo; R R Prado; J A M Carvalho; K Nasir; R S Blumenthal; R D Santos
Journal:  QJM       Date:  2016-01-19

Review 9.  Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.

Authors:  Luigi E Adinolfi; Rosa Zampino; Luciano Restivo; Amedeo Lonardo; Barbara Guerrera; Aldo Marrone; Fabio Nascimbeni; Anna Florio; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742

10.  Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes.

Authors:  Albrecht Ingo Schmid; Julia Szendroedi; Marek Chmelik; Martin Krssák; Ewald Moser; Michael Roden
Journal:  Diabetes Care       Date:  2011-01-07       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.